

# RespireRx Pharmaceuticals

11:25 07 Mar 2022

## RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022

RespireRx Pharmaceuticals Inc interim CEO Arnold S Lipka has updated shareholders about the company's progress in 2021, its internal restructuring, and how it plans to move forward in the current year.

In a letter to shareholders, Lipka noted that the company has implemented an internal restructuring plan through which its two-drug platforms have been reorganized into separate business units and may in the future be organized into private subsidiaries of RespireRx.

Lipka also said the company has implemented an internal restructuring plan with the hope of unlocking what it believes is unrealized value, based upon its two research platforms -- pharmaceutical cannabinoids and neuromodulators.

READ: RespireRx Pharmaceuticals notes publication of paper on GABAkinase KRM-II-81, which it is advancing for epilepsy and pain

For 2022, the company is planning to conduct animal and human pharmacokinetic studies with three new proprietary dronabinol formulations in order to choose the best one for conducting a Phase III clinical efficacy study for obstructive sleep apnea (OSA) in 2023.

Moreover, the company is hoping to conduct a Phase II clinical trial investigating the effects of CX1739 in patients with spinal cord injury (SCI).

RespireRx will also conduct sufficient preclinical IND enabling studies to support an IND for KRM II-81, its lead GABAkinase, allowing the start of Phase I clinical trials in 2023.

Recounting developments in 2021, Lipka said that the company's cannabinoid-focused subsidiary, ResolutionRx, is developing proprietary compounds based around dronabinol, a drug already approved by the US Food & Drug Administration (FDA) that targets the CB1 and CB2 receptors of the brain's endocannabinoid system.

In support of this program, the company has patents pending claiming blood levels, doses, duration of action and intends to submit additional patent applications claiming composition of matter, method of manufacture, and method of treatment for dronabinol and other cannabinoids.

Its neuromodulator platform, EndeavourRx, is made up of two programs -- an AMPAkinase program, which is developing proprietary compounds that are positive allosteric modulators of AMPA-type glutamate receptors; and a GABAkinase program, which is developing proprietary compounds that are PAMs of GABAA receptors.

Lipka noted that recent results from the AMPAkinase program have provided a "great impetus" to conduct a Phase II clinical trial in patients recovering from a spinal injury. Clinical sites have been identified and, pending financing, plans

**Price:** 0.01

**Market Cap:** \$949.08 k

### 1 Year Share Price Graph



### Share Information

**Code:** RSPI

**Listing:** OTCQB

**52 week High Low**  
0.095 0.006

**Sector:** Pharma & Biotech

**Website:** respirerx.com

### Company Synopsis:

*RespireRx Pharmaceuticals Inc is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.*

action@proactiveinvestors.com

have been drafted to update the current CX1739 IND to incorporate a new clinical protocol and conduct the study.

In another program, samples are being developed as a potential breakthrough treatment for treatment-resistant epilepsy and chronic pain.

Despite the successes for the research and development team, Lippa noted that the company's "major challenge has been to raise substantial equity or equity-linked financing to support our research and development plans, while minimizing the dilutive effect to pre-existing stockholders."

He added: "At present, we believe that we are hindered primarily by our public corporate structure, our common stock not being listed on a national exchange, and low market capitalization as a result of our low stock price. We believe that by creating one or more subsidiaries to further the aims of ResolutionRx and EndeavourRx, it may be possible, through separate finance channels, to optimize their asset values and make them more attractive for capital raising as well as for strategic transactions."

The company is also involved in business development efforts with a view to securing strategic partnerships that represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities.

These efforts have focused on engaging with the brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful formulation or manufacturing capabilities, significant subject matter expertise, and financial resources.

Contact Ritika at [ritika@proactiveinvestors.com](mailto:ritika@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of RespireRx Pharmaceuticals named herein, including the promotion by the Company of RespireRx Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual cash compensation of typically up to \$25,000.